Sargramostim

• A Randomized Clinical Trial Investigating Olaparib, Durvalumab (MEDI4736) and UV1 as Maintenance Therapy in BRCAwt Patients with Recurrent O… Pending
  2024-516327-14-00 Phase II 9 countries Nordic Society Of Gynaecological Oncology Clinical Trial Unit
• BreAK CRC (001) trial Recruiting
  2024-512011-45-00 Phase I (FiH) 2 countries Brenus Pharma
• A Phase 3 Trial of Antibody hu3F8 and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in High-Risk Neuroblastoma Patients with Pri… Recruiting
  2023-508587-29-00 Phase II 5 countries Y-mAbs Therapeutics A/S
• PSEUDOVAX – A CANCER VACCINE TARGETING MUTATED GNAS COMBINED WITH IMMUNE CHECKPOINT INHIBITION FOR PATIENTS WITH PSEUDOMYXOMA PERITONEI Recruiting
  2024-517047-30-01 Phase I 1 country Oslo University Hospital HF
• A Randomized, Multicenter, Placebo-controlled, Phase 3 study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF)… Recruiting
  2023-504323-25-01 Phase III 10 countries Greenwich LifeSciences Inc.
• A Study of the Efficacy and Safety of Galinpepimut-S (GPS) for the Treatment of Acute Myeloid Leukemia Compared to Investigator's Choice of … Ended
  2024-516405-23-00 Phase III 5 countries Sellas Life Sciences Group Inc.
• Nivolumab and ipilimumab +/- UV1 vaccination as second line treatment in patients with malignant mesothelioma (the NIPU-study) Ended
  2022-502604-67-00 Phase II/III 4 countries Oslo University Hospital Hf
• Efficacy and safety of UV1 vaccination +/- standard of care as first line treatment of patients with non-small cell lung cancer Ended
  2022-502437-25-00 Phase II 1 country Vestre Viken HF

Showing 1–8 of 8 trials